Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar.
Last week, the European Specialist Nurses Organisations (ESNO) released a document aimed at assisting nurses in the management of switching a patient from a reference biologic to a biosimilar. The guidelines specifically address the role of specialized nurse interactions with patients during the switching process and build upon existing European Commission guidelines for the healthcare community.
“Switching between similar biological medicines needs good management. Nurses play a crucial role in communicating with patients and providing support and reassurance, before, during, and after the switch,” said Ber Oomen, executive director at ESNO, in a statement.
Nurses have firsthand experience in leading the transition between a reference biologic and a biosimilar. In order to address the important interactions nurses have with patients, the guidelines include points around how to better inform and clearly communicate information about biologics and biosimilars.
Specifically, the guidelines contain talking points around the benefits of biosimilars such as increasing patient access to drugs, how to address patient questions or concerns if they are hesitant about switching, and exercising proper pharmacovigilance.
In addition, there are multiple case studies and real-world data included in the document that reinforce biosimilars' safe and effective use. “The quality, safety, and efficacy of biosimilar medicines are assessed and tested with comparability studies (including clinical trials) before the medicine is approved,” read the guidelines.
The guide was created by the ESNO community “based on similar initiatives across Eruope where switching programs are already in place.” For convenience, the authors also created a pocket dictionary for nurses that includes frequently asked questions from patients and how to address them.
“This is built on nurses’ many years of education, and their experience with patients in different therapies. It is a process that requires time, patience, and care… Patients need to know that their healthcare professionals understand the reasoning behind the switch and are confident that it is the right thing to do. This guide aims to achieve that,” said Oomen.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.